Diabetes: Key Markers of Injury and Prognosis

Ian J. Neeland, Kershaw V. Patel

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Diabetes mellitus is a disease defined by biomarkers. The diagnostic criteria rely on elevated blood glucose and glycated hemoglobin levels that reflect risk of microvascular disease (kidney, eye, and peripheral nerves), but studies have not shown that improved glycemic control impacts macrovascular disease (cardiovascular death, coronary heart disease, and stroke). Therefore there is a need for blood-based biomarkers of injury and prognosis in diabetes that can aid the clinician in risk stratification, initiation and monitoring of treatment efficacy, and prognostication for long-term cardiovascular events. Nonglycemic biomarkers such as blood lipids and markers of kidney dysfunction, cardiac injury, hemodynamic stress, inflammation, and subclinical atherosclerosis have a role in cardiovascular disease prognostication. Several novel and emerging biomarkers are under investigation and hold promise for future clinical use. Recently published and ongoing cardiovascular outcomes trials in patients with diabetes will also help to inform the use of markers of injury and prognosis in this population.

Original languageEnglish (US)
Title of host publicationBiomarkers in Cardiovascular Disease
PublisherElsevier
Pages41-51
Number of pages11
ISBN (Electronic)9780323548359
DOIs
StatePublished - Jan 1 2018

Keywords

  • Biomarkers
  • Cardiovascular disease
  • Diabetes mellitus
  • Hemoglobin A1c
  • NT-proBNP
  • Troponin

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Diabetes: Key Markers of Injury and Prognosis'. Together they form a unique fingerprint.

Cite this